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REVIEW ARTICLE
Resistance to immune checkpoint inhibitors in advanced
gastro-oesophageal cancers
Mark A. Baxter 1,2, Fearghas Middleton2, Hannah P. Cagney3 and Russell D. Petty 1,2
Immune checkpoint inhibitors (ICIs) have altered the treatment paradigm across a range of tumour types, including gastro-
oesophageal cancers. For patients with any cancer type who respond, ICIs can confer long-term disease control and significantly
improve survival and quality of life, but for patients with gastro-oesophageal cancer, ICIs can be transformative, as durable
responses in advanced disease have hitherto been rare, especially in those patients who are resistant to first-line cytotoxic
therapies. Results from trials in patients with advanced-stage gastro-oesophageal cancer have raised hopes that ICIs will be
successful as adjuvant and neoadjuvant treatments in early-stage disease, when the majority of patients relapse after potential
curative treatments, and several trials are ongoing. Unfortunately, however, ICI-responding patients appear to constitute a minority
subgroup within gastro-oesophageal cancer, and resistance to ICI therapy (whether primary or acquired) is common.
Understanding the biological mechanisms of ICI resistance is a current major research challenge and involves investigation of both
tumour and patient-specific factors. In this review, we discuss the mechanisms underlying ICI resistance and their potential specific
applications of this knowledge towards precision medicine strategies in the management of gastro-oesophageal cancers in clinical
practice.
British Journal of Cancer https://doi.org/10.1038/s41416-021-01425-7
BACKGROUND
In the past decade, immune checkpoint inhibitors (ICIs) have
reshaped the treatment landscape for many cancers. ICIs target
cell-surface ‘immune checkpoints’—immune inhibitory pathways
that normally function to mediate self-tolerance but that can be
exploited by tumour cells to evade the host immune response.1
Indeed, the best recognised mechanism of evasion of the immune
system by tumour cells is their upregulation of the immunosup-
pressive cell-surface ligands programmed cell death ligand-1 (PD-
L1) and PD-L2. These ligands interact with the T-cell surface
protein programmed cell death-1 (PD-1), resulting in suppression
of T-cell activity via intracellular signalling. The expression of PD-
L1 and PD-L2 has prognostic value across a range of tumour types,
including gastro-oesophageal cancer. PD-L1 is reported to be
expressed by 10–30% of gastro-oesophageal cancer cells,2–4 and
the expression of PD-L1 and PD-L2 is associated with poorer
survival in the neoadjuvant setting.5
The most striking example of the impact of ICIs is seen in
metastatic melanoma, where the anti-PD-1 antibodies nivolu-
mab and pembrolizumab and the anti-cytotoxic T lymphocyte
antigen-4 (anti-CTLA-4) antibody ipilimumab have, within a
decade, helped to extend the median survival of patients in
clinical trials from less than a year6 to up to 5 years currently.7,8
This change in outcome has been driven by durability of
response, which is the hallmark of these agents (unlike the
benefit of other therapies, which tend to diminish with
increased time). Despite this success, not all patients or cancer
types benefit from ICIs and, in those that do, relapse can and
does occur—even in patients who have shown a prolonged
response. This phenomenon is known as resistance and can be
classified as primary or acquired.9 Several common cancers,
including gastro-oesophageal cancer, have an initial low
frequency of response to ICIs (i.e. they show primary resistance);
the rates of primary resistance can be estimated from response
rates to ICI agents. The exact rates of acquired resistance,
however, are poorly reported, and are complicated by the
disputed occurrence of ‘hyperprogression’ and ‘pseudoprogres-
sion’ in some patients10 (Box 1).
Gastric cancer and oesophageal cancer are the fifth and eighth,
respectively, most common cancers globally, and together cause
an estimated 1.25 million deaths worldwide each year.11 Gastro-
oesophageal cancer refers to cancer of the lower oesophagus,
gastro-oesophageal junction and proximal stomach. The location
of the primary lesion determines whether the cancer is considered
and staged as gastric or oesophageal origin. In clinical settings,
gastro-oesophageal cancer is currently classified according to
histological subtype—the main subtypes are squamous cell
carcinoma (SCC) and adenocarcinoma—and site of primary lesion.
Not only are SCC and adenocarcinoma associated with
divergent histology, but also with different biology and aetiolo-
gical factors; their pathogenesis and molecular biology must
therefore be considered separately. Oesophageal SCC predomi-
nates in the upper and mid-oesophagus and is associated with
smoking and alcohol, with a 5-year survival of ~15%.12 Gastro-
oesophageal adenocarcinoma—in particular, adenocarcinoma of
the lower oesophagus and gastro-oesophageal junction—is
rapidly increasing in incidence in developed countries.13 It has a
similarly poor 5-year survival to SCC (15–20%),14,15 and median
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survival in unselected patients in the advanced setting is less than
a year.16
The mainstay of first-line treatment in patients with advanced
gastro-oesophageal cancer is platinum-based chemotherapy, with
agents such as docetaxel, paclitaxel and irinotecan used following
progression. For cases of advanced gastro-oesophageal SCC or
adenocarcinoma that are refractory to chemotherapy, durable
responses have been seen using ICIs (18.0 months median
duration of response in KEYNOTE-06117) but most patients
(~85%) have primary resistance and do not benefit from ICI
monotherapy. Those who do respond often develop acquired
resistance. Accurately identifying subgroups of patients with
gastro-oesophageal cancer who are likely to benefit significantly
from ICIs is a therapeutic challenge. Currently, biomarkers for
response to ICIs include the extent of microsatellite instability, PD-
L1 expression and, potentially, presence of the Epstein–Barr virus
(EBV). Alongside identifying biomarkers to predict response,
research has also focused on uncovering mechanisms of
resistance to ICIs, but identifying such mechanisms is challenging
in gastro-oesophageal cancer owing to the complex disease
biology.18,19 In this review, we discuss the clinical impact of ICIs on
the treatment of gastro-oesophageal cancer thus far, examine
mechanisms of resistance, and explore how resistance can
potentially be circumvented in order to effectively treat patients.
MOLECULAR CHARACTERISTICS OF GASTRO-OESOPHAGEAL
CANCER
The clinical classification of gastro-oesophageal cancer was
outlined above; work carried out over the past decade has
focused on characterising specific molecular subtypes. This work
suggests that there could be specific molecular subgroups of both
gastric and oesophageal adenocarcinomas that might be sensitive
to ICIs, and that oesophageal SCC needs to be considered
separately.20
Gastric cancer
The Cancer Genome Atlas (TCGA) has profiled gastric cancer into
four subtypes: EBV (9%); microsatellite instability (MSI; 22%);
genomically stable (GS; 20%); and chromosomal instability (CIN;
50%).21 The subtypes appear to have prognostic value, with EBV
having the best prognosis and GS having the worst.22 Within the
TCGA cohort, the EBV subtype was enriched for amplification of the
genes that encode PD-L1 and PD-L2 and, with the link between MSI,
CD8+ T-cell infiltration and ICI response now being well recog-
nised,23,24 it is therefore likely that both the EBV and MSI subgroups
might be susceptible to ICIs. By contrast, GS tumours appear to be
immune evasive, and the CIN subtype is associated with amplifica-
tion of receptor tyrosine kinases (RTKs) and high levels of somatic
copy number change. Several of these RTKs have been linked to the
local immune landscape and are candidates for molecularly targeted
therapies. Further analysis of the immune infiltrate (a high degree of
macrophage infiltration with T-cell exclusion) and interferon-γ (IFN-γ)
levels (low levels) showed that CIN tumours were most likely to be
immunologically evasive22 and respond poorly to ICIs.20
Oesophageal cancer
Oesophageal SCC. On the basis of molecular features, oesopha-
geal SCC more closely resembles SCC of other organs than it
does oesophageal adenocarcinoma. This observation might
have therapeutic implications as oesophageal SCC and adeno-
carcinoma have historically been treated with similar systemic
regimes—this approach may need to change. Oesophageal SCC
has three molecular subclasses: ESCC1, which is associated with
alterations in the nuclear factor erythroid 2-related factor 2
(NRF2) pathway and is present in an East Asian population;
ESCC2, which is associated with a NOTCH1 mutation and is
present in an Eastern European and South American population;
and ESCC3, which is associated with activation of the
phosphoinositide 3-kinase (PI3K) pathway and is predominant
in a North American population.12
Oesophageal adenocarcinoma. An integrated genomic analysis of
164 oesophageal cancers found that oesophageal adenocarci-
noma strongly resembled the CIN variant of gastric cancer, with
some variation in molecular features such as hypermethylation.25
Further work by the UK Oesophageal Cancer Clinical and
Molecular Stratification (OCCAMS) group on 129 oesophageal
and gastro-oesophageal junction adenocarcinomas defined three
mutational signatures: a BRCA-like signature (15%); a mutagenic
signature with significant neoantigen load and tumour mutational
burden (TMB) (53%); and a C > A/T signature associated with
ageing (32%).18 The OCCAMS consortium subsequently used
combined multi-omic characterisation of 551 oesophageal ade-
nocarcinoma samples to identify 77 driver genes with a mean of
4.4 driver events per tumour, which are commonly derived from
mutations rather than copy number events. These events are
often associated with numerous exclusive or co-occurring
dysregulated signalling pathways, highlighting the challenge
heterogeneity brings to identifying a specific therapeutic target.19
Although felt to genomically resemble the immune evasive CIN
variant of gastric cancer, oesophageal adenocarcinoma has a
higher TMB compared with gastric cancer and other tumour types,
with 9.9 mutations/Mb, ranked behind only those cancers in which
ICIs have been approved (e.g. melanoma, lung and bladder
cancer).26
CURRENT IMPACT OF ICIS IN ADVANCED GASTRO-
OESOPHAGEAL CANCERS
ICIs have shown promising activity in gastro-oesophageal cancer
(Table 1), with response rates in pre-treated patients ranging from
11 to 24%, depending on the combined positivity score (CPS; the
ratio of cells (both tumour and immune) expressing PD-L1 relative
to the number of viable tumour cells).17 The response rates appear
constant regardless of line of therapy,17,27,28 which suggests that a
distinct population of patients who will benefit exists. When
responses occur, they often prove durable. Currently, the best
predictive biomarkers of response are the extent of MSI and PD-L1
expression.28 However, although response rates are in excess of
50% in MSI-high tumours, these tumours constitute only ~4% of
gastro-oesophageal cancers.28 For this reason, much research has
focussed on the expression of PD-L1. Interestingly, several
antibodies for immunohistochemistry exist; their varying specifi-
cities and sensitivities29 are likely to account for the range of
expression estimates and might also influence the ability to
accurately quantify a patient’s tumour expression and therefore
eligibility for therapy. PD-L1 expression has a good negative
predictive value for response (negative expression is associated
with a response rate (RR) of 2–6% for ICI monotherapy) but a
poorer positive predictive value (a PD-L1 CPS ≥ 1 is associated
with a RR of 15–16%, and a PD-L1 CPS ≥ 10 is associated with a RR
of 24–25%). There is a need for better biomarkers to drive
personalised treatments.
Box 1 Definitions of types of tumour response seen with
immune checkpoint inhibitors.
Type of response Definition.
Hyperprogression Rapid increase in rate of tumour progression on commencing
ICI therapy.
Primary resistance No response to initial therapy.
Acquired resistance Initially response to ICI observed but after a period of time
progression seen.
Adaptive resistance Cancer is recognised by the immune system but protects
itself by adapting to the immune attack; can manifest as primary or acquired
resistance.
Pseudoprogression Initial growth in tumour burden followed by a response.
Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal. . .
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ICIs in pre-treated patients
CTLA-4 inhibitors were the first ICIs to be trialled in advanced
gastro-oesophageal cancer, but ipilimumab and tremelimumab
both showed limited success in the Phase 2 setting.30,31 A Phase
1b/2 study with tremelimumab and the PD-L1 inhibitor durvalu-
mab, either alone or in combination, again demonstrated low
response rates.32 The first randomised Phase 3 trial to show
promise using a single-agent ICI—the PD-1 inhibitor nivolumab—
was ATTRACTION-2.33 In pre-treated patients with advanced
gastric or gastro-oesophageal cancer, nivolumab conferred a
survival advantage over placebo with a median overall survival of
5.3 months versus 4.1 months (hazard ratio [HR] 0.62, P < 0.0001), a
response rate of 11% versus 0%, and 1-year survival of 27% versus
12%, suggesting a significant advantage for a subgroup of
patients.
The KEYNOTE-061 trial compared pembrolizumab to paclitaxel
in the second-line setting.17 Importantly, the PD-L1-negative
subgroup was terminated because of a worse survival compared
to paclitaxel, again highlighting the negative predictive value of
low PD-L1 expression. In patients with a CPS ≥ 1, median
progression-free survival (PFS) was inferior with pembrolizumab
(1.5 months versus 4.1 months with paclitaxel, HR 1.27). Although
median overall survival (OS) trended towards significance, the
one-sided alpha of 0.0135 was not met (9.1 months versus
8.3 months, HR 0.82, P= 0.0421). Response rates ranged from 16%
to 24%, depending on the CPS. Of note, the survival curves
crossed, indicating the potential existence of two distinct
populations—one that derived benefit from ICI therapy and the
other that derived absolutely no benefit and accounted for the
initial steep fall in the survival curve of the pembrolizumab arm.
The existence of these distinct populations highlights the
importance of choosing the correct treatment for individual
patients.34
As highlighted above, oesophageal SCC differs biologically from
oesophageal adenocarcinoma, yet appears to benefit from the use
of nivolumab or pembrolizumab in the second-line setting. The
ATTRACTION-335 study demonstrated a survival advantage for
nivolumab over chemotherapy (median OS 10.9 months versus
8.4 months; HR 0.77, P= 0.019), while the KEYNOTE-181 study
demonstrated a survival advantage for pembrolizumab over
chemotherapy in patients with SCC and a CPS ≥ 10 (median OS
10.3 months versus 6.7 months; HR 0.69).36 There was no survival
advantage for oesophageal SCC CPS < 10 or adenocarcinoma
regardless of CPS.
ICIs in the first-line setting
Early-phase trials of combination immunotherapy in the later
setting indicate marginal improvements in outcome, but at the
risk of greater toxicity.37 Trials have subsequently moved to
explore the role of ICIs in the first-line setting: as a single agent, or
in combination with either chemotherapy or another ICI; and in
maintenance therapy following induction chemotherapy.
ICIs alone or combined with another ICI or chemotherapy. The
KEYNOTE-062 study38 explored the use of pembrolizumab or
chemotherapy in combination or alone as first-line treatment of
advanced gastric or gastro-oesophageal junction adenocarci-
noma. Pembrolizumab alone was non-inferior to chemotherapy
for survival in patients with CPS ≥ 1, albeit with a lower PFS and
response rate. The survival curves, similar to those in KEYNOTE-
061, again crossed. The greatest benefit of ICI therapy was seen in
those with CPS ≥ 10 (median OS 17.4 months versus 10.8 months).
However, the combination arm was not superior to chemotherapy
alone in either OS or PFS, regardless of the CPS, and was
associated with higher toxicity (73% of patients had grade 3–5
toxicities). The HR for the combination arm was 0.85 for both the
CPS ≥ 1 (257 patients) and ≥10 arms (99 patients). The lack of
significance might be partly explained by lowering the power of
the study with co-primary endpoints and smaller patient numbers.
Similarly, the ATTRACTION-4 study investigated the use of
nivolumab with chemotherapy in an Asian population including
patients with gastric or oesophageal adenocarcinomas. There was
a PFS benefit but no difference in OS between the groups (median
OS 17.5 months versus 17.2 months; HR 0.9, P= 0.259). Many
patients received subsequent lines of treatment on progression,
including a high rate of crossover to ICIs, which might have
influenced survival analysis.39 This might also provide further
support for the evidence that ICIs can be effective regardless of
line of therapy.
By contrast, the international CheckMate 649 study40 investigat-
ing the use of nivolumab with chemotherapy found a survival
advantage conferred by combination therapy in the CPS ≥ 5 group
(median OS 14.4 months versus 11.1 months, HR 0.71). OS was the
primary endpoint and, importantly, 473 patients received combi-
nation therapy, which increased the study power.
The KEYNOTE 590 study41 investigated chemotherapy with or
without pembrolizumab in the first-line setting for advanced
gastro-oesophageal cancer (both oesophageal adenocarcinoma
and SCC were included). In the SCC population, pembrolizumab
conferred a survival advantage in the population as a whole
(median OS 12.6 months versus 9.8 months, HR 0.72) but
particularly in the CPS ≥ 10 group (median OS 13.9 months versus
8.8 months, HR 0.57).
ICIs in maintenance therapy following induction chemotherapy.
Another therapeutic approach that has been investigated involves
maintenance therapy with ICI after induction chemotherapy; for
example, the JAVELIN-100 trial of avelumab, which targets PD-L1,
versus continuation of chemotherapy.4 However, in this study,
38% of patients did not progress to the maintenance stage. In
those who were randomised, no difference was observed in the
primary endpoint of median OS in all patients or the response
rate; however, the 2-year OS was improved, and the duration of
response was longer for avelumab. A retrospective post-hoc
analysis of 137 patients with CPS ≥ 1 demonstrated a median OS
of 14.9 months versus 11.6 months (HR 0.72, 95% confidence
interval (CI) 0.49–1.05), favouring avelumab. Avelumab, in contrast
with nivolumab and pembrolizumab, targets PD-L1; there is some
evidence that anti-PD-1 ICIs, which have shown benefit in gastro-
oesophageal cancers, deliver different clinical outcomes to ICIs
that target PD-L1,42 which might be an additional relevant factor
in explaining the negative outcome of this trial. Ongoing studies,















Fig. 1 Patterns of disease response to immune checkpoint
inhibitors. Disease burden is on the x-axis and time on the y-axis.
All patients begin with a level of disease burden. The subsequent
patient of disease response can fall into one of five broad categories;
hyperprogression, primary resistance, pseudoprogression, acquired
resistance or durable response.
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maintenance treatment with ICIs will help to address this issue, as
well as clarify the role of maintenance treatment with ICIs more
broadly in gastro-oesophageal cancers.
MECHANISMS OF ICI RESISTANCE IN GASTRO-OESOPHAGEAL
CANCER
The trial results outlined above suggest that a combination
regimen with chemotherapy and ICI should now be first line for
patients with advanced oesophageal SCC and a CPS ≥ 10, or for
those with advanced gastro-oesophageal or oesophageal adeno-
carcinoma and a CPS ≥ 5. However, they also highlight that not all
patients benefit from ICI therapy, and the importance of under-
standing the underlying reasons for this resistance.
Resistance can be either primary or acquired (Box 1 and Fig. 1)
and can involve both intrinsic signalling and the tumour
microenvironment (TME) (Fig. 2). Involvement of the immune
system in promoting resistance is termed ‘adaptive’. The interac-
tion between host and tumour is constantly evolving, and
resistance can manifest at any disease stage.
Some patients appear to experience a dramatic acceleration in
disease progression following commencement of immune check-
point blockade, termed hyperprogression, which is associated
with very poor survival.10 This phenomenon must be distin-
guished from pseudoprogression, where a tumour response is
seen following an initial apparent increase in disease burden
(Box 1).
Hyperprogression
Hyperprogression is a controversial topic, with opponents
contending it is the natural history of the disease. Multiple
definitions exist, but the underlying theme is the occurrence of a
rapid escalation of tumour progression on commencement of ICI
therapy.43–45 Retrospective analyses of large studies have shown
rates of hyperprogression of 4–17% with ICIs (much higher than
with chemotherapy); the effect is not tumour-specific and is
associated with decreased PFS and OS.45–47 The underlying
mechanism is unknown, but evidence points to a role for
alterations in the gene that encodes the epidermal growth factor
receptor (EGFR) and amplification of MDM2/4, in addition to the
presence of M2-like macrophages, which promote tumorigen-
esis.45,48 Notably, EGFR alterations are present in 19% of
oesophageal SCCs and 15% of oesophageal adenocarcinomas as
an oncogenic driving mechanism.12
In the Asian ATTRACTION-2 study,33 which is the only study
comparing ICI therapy with best supportive care only, the survival
curves do not cross. If true hyperprogression was occurring,
crossing of the survival curves might be expected as a subgroup of
patients who received an ICI would experience an acceleration of
their natural disease trajectory. This observation could suggest
that what is perceived as hyperprogression in other studies
comparing ICI therapy with an active control arm in gastro-
oesophageal cancer might, in fact, be the result of a group of
patients who derive absolutely no benefit from ICI therapy
demonstrating the natural history of the disease. This natural
history would appear worse than control arms of active
chemotherapy and be similar to the response observed in other
trials with best supportive care alone arms in this setting.49
Primary resistance
Patients who do not respond to initial therapy have primary
resistance. Although stable disease can be associated with patient
benefit in some cases, considering that the majority of patients
with advanced stage gastro-oesophageal cancer are often very
symptomatic and have high tumour burdens, then ideally a
reduction in tumour volume should be achieved. In this clinical
context, if stable disease is considered as resistance, primary
resistance accounts for ~85% of patients. Primary resistance is
driven primarily by intrinsic tumoural cellular signalling and the
TME. Host-related factors such as age, human leukocyte antigen
(HLA) type, diet and the gut microbiome have also been
postulated to contribute to resistance, but data are preliminary
and no clear therapeutic targets have been identified.
Intrinsic tumoural cell signalling
In gastro-oesophageal cancer, primary resistance to ICIs is driven
by signalling involving a complex interplay of pathways including
the extracellular signal-regulated kinase/mitogen-activated pro-
tein kinase (ERK/MAPK), WNT–β-catenin and IFN-γ signalling
pathways, which together influence the cell-surface expression
of immune checkpoint molecules. The end result is down-
regulation of T-cell function.
The MAPK pathway, which encompasses activation of RAS, RAF,
MAPK and ERK kinase (MEK) and ERK/MAPK is upregulated in
52–60% of gastro-oesophageal adenocarcinomas.50,51 This path-
way plays a critical role in cell fate decisions within CD8+ T cells
including influencing proliferation and survival.52 In tumour cells,
activation of the MAPK pathway results in increased levels of
vascular endothelial growth factor (VEGF), which has an immuno-
suppressive effect—it inhibits T-cell function and recruitment,
increases the recruitment of regulatory T (TREG) cells and myeloid-
derived suppressor cells (MDSCs), and hinders the differentiation
and activation of dendritic cells.53,54 The downstream
Akt–mammalian target of rapamycin (mTOR) pathway has also
been shown to drive the expression of PD-L1 expression in non-
small cell lung cancer.55
The PI3K pathway (including AKT–mTOR) is altered in ~59% of
oesophageal SCC and 76% of adenocarcinomas.12 As noted above,
this pathway has been shown to regulate tumour PD-L1
expression55 and pathway inhibition has been shown to enhance
the infiltration of CD8+ T cells.56 Loss of expression of phosphatase
and tensin homologue (PTEN), a negative regulator of PI3K
signalling, results in the activation of PI3K, which correlates with
ICI resistance in melanoma.56 Although somatic PTEN mutations
are uncommon in oesophageal cancer, alterations in PTEN
expression commonly occur in oesophageal adenocarcinoma. In
a study of 117 resected oesophageal adenocarcinomas, 38%
showed absent or markedly reduced PTEN staining by
immunohistochemistry.57
Activation of WNT–β-catenin signalling in tumour cells is
frequently associated with poor spontaneous T-cell infiltration
across most human cancers,58 and this pathway is aberrantly
activated in 30–50% of gastric cancer tissues.59 Work by the
OCCAMS group suggests a three-way association between the
activation of Wnt, hypermutation and the loss of immune
signalling genes.19 Activation of the WNT–β-catenin pathway is
essential for T-cell differentiation, effector function and migra-
tion.60 Through its main transcription factor, T-cell factor (TCF-1),
this pathway promotes the differentiation of naïve CD8 cells into
memory cells rather than effector cells, reducing the immediate
anti-tumour effect.58 It also plays a role in restricting T cells from
the immediate TME, thereby contributing to the ability of the
tumour to evade the immune response. Analysis of TCGA revealed
that activating mutations in β-catenin signalling molecules were
enriched three-fold in non-T-cell-inflamed tumours relative to T-
cell-inflamed tumours.61 With a T-cell-inflamed TME associated
with a better response to ICIs, this evidence supports a role for
β-catenin in ICI resistance.
IFN-γ plays a key role in the function of effector T cells, with
reports of both positive and negative effects on anti-tumour
immune responses.62 Tumour-specific T cells produce IFN-γ on
recognising their respective antigen on tumour cell surfaces or via
an antigen-presenting cell, which results in enhanced tumour
antigen presentation, recruitment of immune cells and direct anti-
proliferative and pro-apoptotic effects on cancer cells.63 IFN-γ can
also induce the expression of PD-L1 in gastric cancer.64 In gastric
Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal. . .
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cancer cell lines, IFN-γ given with PD-L1 antibodies had an
enhanced effect compared with PD-L1 antibody monotherapy,64
while in clinical samples PD-L1 expression is significantly
associated with intra-tumoural IFN-γ and stromal CD8+ T cells.65
Taken together, these results suggest that gastric cancer patients
with constitutively high levels of IFN-γ should be more susceptible
to ICIs than patients with low levels. Consequently, tumour cells
might downregulate or mutate molecules involved in the IFN-γ
signalling pathway.66
The TME. The function of T cells and their presence in the TME
are key elements of the immune response to cancer. A T-cell-
inflamed TME improves the efficacy of immune checkpoint
blockade, whereas non-T-cell-inflamed tumours rarely benefit.67
Within the TME, cells surrounding the tumour can influence ICI
resistance mechanisms. These include TREG cells, MDSCs, tumour-
associated macrophages (TAMs) and cancer-associated fibroblasts
(CAFs),68 which all exist within the dynamic operations of the
immune system. Their responses are tightly regulated via
chemokine-mediated negative-feedback systems.
The presence of TREG cells is common in many human tumours,
including gastro-oesophageal cancers, and higher levels of this
cell type are associated with a poorer prognosis.69 TREG cells have
a vital role in maintaining self-tolerance,70 using inhibitory
cytokines (e.g. IL-10, transforming growth factor β (TGF-β) and
IL-3571) to suppress T-cell responses, and also play a role in
neoangiogenesis, which facilitates metastasis.72 Depletion of TREG
cells in murine models has been shown to restore and enhance
anti-tumour immunity,73,74 although this approach increases the
potential for the development of autoimmune disorders.75 The
ability to increase the ratio of effector T cells compared with TREG
cells is associated with a positive response to ICIs,76 thereby
supporting a role for TREG cells in mediating resistance to ICI.
MDSCs are immature myeloid cells that play a key role in the
suppression of both the innate and adaptive immune response
and in promoting angiogenesis, tumour cell invasion and
metastasis.77 Their presence is associated with more advanced
stage and poorer prognosis, in gastric and oesophageal cancers
specifically.78 MDSCs are regulated by a complex network of
signalling molecules, including IL-6, IL-10, granulocyte colony-
stimulating factor (G-CSF), IFN-γ and VEGF, which control MDSC
recruitment and activation in the TME.79 These molecules appear
to signal primarily through the PI3K–Akt and Janus kinase
(JAK)–signal transducer and activator of transcription (Stat)
pathways.80 The C–C motif chemokine ligand 2 (CCL2)– C–C motif
chemokine receptor 2 (CCR2) pathway also plays a role in MDSC
recruitment in gastric cancer.81 The presence of MDSCs appears to
predict reduced efficacy of ICI therapy possibly as a consequence
of their role in TREG cell expansion, inhibition of effector T cells via
CD40, TFG-β and IL-10 and inhibition of natural killer (NK) cell
function.82 Therefore, reducing the numbers of MDSCs, preventing
their recruitment or reprogramming their function could enhance
the response to ICIs.
Macrophages that populate the TME (TAMs) can be classified as
‘classically activated’ (M1 or type 1) and ‘alternatively activated’
(M2 or type 2) on the basis of their surface molecules, cytokine
profile and metabolism.83 M1 macrophages promote a pro-
inflammatory, anti-tumour immune response,84 whereas M2
macrophages promote tumorigenesis. M2 macrophages also play
a key role in metastasis by producing growth factors and
proteolytic enzymes and triggering various inhibitory immune
checkpoints in T cells.84 Higher frequencies of M2 TAMs are
associated with poor prognosis in a range of cancers, including
gastric and oesophageal cancers.85–87 In gastro-oesophageal
cancer, increased M2 TAM infiltration is associated with increased
PD-L1 expression and therefore may be associated with increased
efficacy of ICIs.
CAFs comprise one of the most abundant components of the
TME, contributing to the extracellular matrix structure of tumour
cells as well as to tumorigenesis. Their presence correlates with
poorer outcomes in both oesophageal adenocarcinoma and
gastric cancer.88,89 CAFs secrete various chemokines that down-
regulate both the innate and adaptive immune responses;90 for
example, secretion of TGF-β by CAFs increases the recruitment of
MDSCs and TREG cells while inhibiting the function of NK cells,
dendritic cells and CD8+ T cells.83 As ICI therapy requires an
























Fig. 2 The impact of intracellular tumour cell pathways and the tumour microenvironment on cytotoxic T cells in gastro-oesophageal
cancer. The figure depicts the various influences on cytotoxic T-cell function relating to the signalling pathways within the tumour itself as
well as the tumour microenvironment (TME). EGFR epidermal growth factor receptor, IFNy interferon y, PTEN phosphatase and tensin
homologue, MAPK mitogen-activated protein kinase, PI3K phosphoinositide 3-kinases, β-cat β-catenin, TCF-1 T-cell factor 1, APC antigen-
presenting cell, VEGF vascular-endothelial growth factor, MDSCs myeloid-derived suppressor cells, TAM tumour-associated macrophages, PD-
L1 programmed death ligand 1, PD-L2 programmed death ligand 2, CTLA-4 cytotoxic T lymphocyte antigen 4.
Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal. . .
MA. Baxter et al.
6
immune response, the presence of CAFs has been associated with
a poorer response to ICIs.91
Acquired resistance
Although dramatic and sustained responses to ICIs have been
seen across a range of tumour types, not all such responses are
maintained. Patients who initially respond to ICIs but after a period
of time progress are said to have acquired resistance. Acquired
resistance can occur owing to a loss of T-cell function, such as
altered antigen presentation and IFN-γ signalling, development of
tumour or β2-microglobulin (β2M) mutations, and an evolving
immune response.
Loss of T-cell function. Changes in the functionality of anti-
tumoural T cells have been observed in patients with advanced
melanoma who underwent adoptive T-cell transfer, with patients
who relapsed showing a lack of the cytotoxic activity that was
initially observed.92 This loss of T-cell response can result from a
reduction in antigen presentation, particularly owing to the loss or
mutation of β2M.93 β2M is a key component of MHC class I
molecules and its genetic deficiency in embryonic stem cells
results in their failure to be recognised by CD8+ T cells.94 Similarly,
tumour β2M deficiency predicts poor outcomes in several cancers
and also predicts resistance to ICI in non-small-cell lung cancer
and melanoma.95 Interestingly, β2M mutations have been
demonstrated following progression on anti-PD1 therapy in
gastro-oesophageal adenocarcinoma, but a β2M mutation at
baseline does not exclude an initial ICI response.96 This supports
the concept that acquired resistance is likely a multifactorial
process.
Mutation of JAK1/2 is also a potential mechanism of acquired
resistance to ICIs.95 Loss of function of JAK1/2 results in the
absence of IFN-γ-mediated signalling and thus tumour immune
evasion. This may be relevant to gastro-oesophageal cancer as—
IFN-γ signalling through the cGAS/STING pathway is associated
with increased PD-L1 expression and better outcomes with
chemotherapy in the neoadjuvant setting.65
An evolving immune response. The immune response is con-
stantly evolving and a balance exists between pro-inflammatory
and inhibitory pathways. The goal of ICI therapy is to stimulate the
pro-inflammatory response. Multiple T-cell inhibitory checkpoints
exist within the TME of oesophageal adenocarcinoma including
those induced by PD-L1, PD-L2, LAG-3, IDO-1, CLTA4 and TIM-3.97
IDO-1, for example, is present in ~20% of oesophageal cancer
specimens and has been shown to correlate with immune
tolerance and poorer outcomes,98 whereas in melanoma, it
appears that CD8+ T cells can drive upregulation of inhibitory
checkpoint molecules, probably as part of an autoregulatory
negative-feedback mechanism.99 We therefore conclude that
acquired resistance to ICI therapy in gastro-oesophageal cancer
could emerge if the co-existing inhibitory pathways are upregu-
lated, thus negating the pro-inflammatory effect of ICIs.
Monitoring mechanisms of resistance
The relationship between the tumour and the immune system is
constantly evolving and it is therefore vital that changes in tumour
genetics are monitored over time. Comprehensive longitudinal
assessment of patient and tumour biospecimens during treatment
is an emerging strategy. This strategy, which can make use of
serial circulating tumour DNA (ctDNA) samples or serial biopsy
specimens, was adopted by the Personalised Antibodies for
Gastro-Esophageal Adenocarcinoma (PANGEA) study.100 Such an
approach used longitudinal biopsy samples in melanoma to
demonstrate that adaptive immune signatures in samples
obtained early during the course of treatment were highly
predictive of the response to ICIs. Importantly, analysis of the
specimens enabled the identification of potential mechanisms of
therapeutic resistance.101
A longitudinal approach is of great importance for gastro-
oesophageal cancer given the heterogenous nature of the disease
and the development of co-existing clones with differing
mutational patterns both before and during treatment, as
demonstrated by a 2020 publication that reported on the use of
















































Boosting the host immune response









Fig. 3 Current/proposed strategies to overcome resistance to immune checkpoint inhibitors. The figure depicts the proposed strategies—
targeting intracellular pathways, combination ICI and boosting the host immune system. Potential specific targets are also highlighted. EGFR
epidermal growth factor receptor, VEGF vascular endothelial growth factor, MEK mitogen-activated protein kinase kinase, PI3K
phosphoinositide 3-kinases, AKT protein kinase B, mTOR mammalian target of rapamycin, β-cat β-catenin, PD-L1 programmed death ligand
1, PD-1 programmed cell death protein 1, CTLA-4 cytotoxic T lymphocyte antigen 4, TIGIT T-cell immunoreceptor with Ig and ITIM domains,
LAG-3 lymphocyte-activation gene 3, MHC major histocompatibility complex, TCR T-cell receptor.
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of 388 samples across 18 individuals with metastatic oesophageal
adenocarcinoma.102 The tumour samples were obtained either
during surgery or from warm autopsy. Analysis revealed multiple
subclones which each appeared to seed multiple metastatic sites;
these subclones seemed to have originated from the primary site.
This development of subclones has been termed ‘clonal diaspora’.
The spatial discordance between the primary lesion and meta-
static sites was also observed in tumour samples from the PANGEA
trial.103
It is also important to note that gastro-oesophageal adeno-
carcinoma appears to display both temporal and spatial
heterogeneity in terms of TMB and PD-L1 expression before
and after chemotherapy.104,105 Maron et al.105 found that the
genomic landscape identified by ctDNA next-generation
sequencing (NGS) was similar, but not identical, to tumour
NGS suggesting that using ctDNA alongside tumour NGS may
provide a mechanism to identify early and target intra-patient
heterogeneity. The development of subclones and the reported
changes in mutational signature, TMB and PD-L1 expression
induced by treatment are clinically relevant as they might
indicate a change in the signalling pathways and driver
mutations, thus potentially altering the immune environment
and the response to cancer therapy.
Obtaining serial biopsy samples can be challenging for
numerous reasons, including patient preferences and the lack of
an accessible metastatic site to target. One solution might lie in
the use of ctDNA, which could also facilitate monitoring of the
response to treatment. Studies of gastro-oesophageal cancer and
in other tumour groups have shown that ctDNA could help to
identify patients with poorer prognosis disease at baseline,
monitor response to therapy and elucidate emerging resistance
mechanisms.105,106
CURRENT STRATEGIES TO OVERCOME RESISTANCE TO ICIS IN
PATIENTS WITH ADVANCED GASTRO-OESOPHAGEAL CANCER
An increasing knowledge of the mechanisms that underlie ICI
resistance is driving efforts to establish new therapeutic strategies
to improve response rates and outcomes in patients with gastro-
oesophageal cancer. If, as proposed by Powers and colleagues,107
cancer has an ‘immune set-point’—an equilibrium between
factors that promote or suppress anti-cancer immunity—then
the goal of overcoming ICI resistance is to turn an immunologi-
cally ‘cold’ TME into a more inflamed ‘hot’ state by increasing the
number of effector T cells and the presentation of neoantigens
while dampening immune suppression by regulatory T cells and
co-existing immune checkpoints. Most patients with gastro-
oesophageal cancer are CIN, with a low immune signature
expression, which explains why response rates to single-agent
therapy are low.22 Consequently, the focus has turned to
combination therapies using both novel and established agents
(Fig. 3).
Boosting the immune response
Chemotherapy can be used to increase the TMB via DNA damage,
with a subsequent increase in antigen presentation and, therefore,
in immune response. Chemotherapy (including platinum agents)
also has a role in reprogramming the immunosuppressive effect of
MDSCs by altering their sensitivity to apoptosis.108 An example of
where this has been trialled is the KEYNOTE-062 study, in which
pembrolizumab was used in conjunction with chemotherapy for
the treatment of patients with advanced gastric or gastro-
oesophageal junction adenocarcinoma.27 The same principle of
inducing DNA damage applies to the use of inhibitors of poly(ADP
ribose) polymerase (PARP) and radiotherapy—chemoradiation
increases the TMB and exposes antigens109—and the use of ICIs
with chemoradiation in resectable gastric cancer is currently under
investigation (NCT03776487).
Novel approaches to boosting an immune response include the
use of histone deacetylase inhibitors (HDACi). HDACi increase the
expression of both MHC class I and II and thus presentation of
tumour-associated antigens.110 This results in enhanced activation
of a cytotoxicity T-cell response.
Combining immune therapy regimens
With the knowledge that negative immune checkpoints are
upregulated as part of acquired resistance, combination immune
therapy regimens are being tested in gastro-oesophageal cancer.
For example, CheckMate 032 investigated the combination of
nivolumab plus ipilimumab in patients with metastatic gastro-
oesophageal cancer.37 Although the Phase 2 non-randomised
study showed promise in the first-line setting, the drug combina-
tion in the subsequent Phase 3 CheckMate-649 study was
terminated early. The reason for this is not yet public, but is likely
either due to lack of efficacy, increased toxicity or both. The
challenge of combination strategies is to balance efficacy with the
increase in immune-related adverse events, particularly in a
population that is often older with multiple co-morbidities.
Targeting intracellular signalling pathways
Cellular signalling by tumour cells can also be targeted, with HER2,
VEGF and MEK providing promising targets.
Overexpression or amplification of HER2 is common in
oesophageal adenocarcinoma (30% amplification in TCGA; 32.2%
HER2-positive gastro-oesophageal junction in TOGA screening
cohort).14 The HER2/ERBB2 receptor monoclonal antibody trastu-
zumab not only prevents receptor dimerisation and, thus,
downstream signalling, but also interacts with the innate immune
system to recruit effector T cells.111 HER2-specific antibodies can
also trigger NK-cell-mediated antibody-dependent cellular cyto-
toxicity.112 These results provide a biological rationale to combine
anti-HER2 therapy with ICI in gastro-oesophageal cancer and are
supported by data from two Phase 2 trials using trastuzumab and
margetuximab, respectively, with pembrolizumab.113,114 These
combinations are the focus of the ongoing KEYNOTE-811
(NCT03615326) and MAHOGANY (NCT04082364) studies.
VEGF signalling is involved in dampening the immune response
by inhibiting T-cell recruitment, effector T-cell function and
dendritic cell maturation as well as by stimulating TREG cells
and MDSCs. Inhibiting the VEGF receptor in combination with the
use of ICIs could therefore increase response rate. This strategy
was effective in the IMbrave150 study in hepatocellular cancer.115
As VEGF signalling often promotes MAPK pathway activation,
inhibitors of MEK and PI3K might also be of benefit.116 Similarly,
the key role and common mutations of the Wnt–β-catenin
pathway in gastro-oesophageal cancer indicate this pathway
could also be targeted.
Some of these pathways are currently being investigated in a
Phase 1b/2 umbrella trial of chemotherapy and the PD-L1 inhibitor
atezolizumab with ramucirumab (VEGF inhibitor), cobimetinib
(MEK inhibitor), tiragolumab (anti-TIGIT; TIGIT is another immune
checkpoint protein), linagliptin (an inhibitor of dipeptidyl pepti-
dase 4 (DPP-4)), BL-8040 (a CXCR4 antagonist) or PEGPH20
(PEGylated recombinant human hyaluronidase) (NCT03281369).
DPP-4 plays a role in lymphocyte migration,117 CXC chemokine
receptor 4 (CXCR4) promotes metastatic homing in HER2-positive
oesophageal cancer118 and PEGPH20 is a stromal modifying agent
that depletes hyaluronan and thus alters biophysical and
molecular signalling pathways.119
CONCLUSIONS
ICIs have been transformative, with sustained responses seen
across a range of tumour types. However, the majority of patients
with gastro-oesophageal cancer fail to respond to ICI therapy, and
many of those who initially respond progress eventually. To
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broaden applicability, we need to understand and address primary
and acquired resistance. Resistance to ICIs is complex and
multifactorial, involving tumour and patient factors in a bidirec-
tional interaction. So far, the mechanistic understanding of
resistance is incomplete. However, resistance mechanisms seen
in other tumour types have provided many hypotheses that
require further investigation in the context of gastro-oesophageal
cancer.
Combination therapies have been the main approach for
current Phase 3 clinical trials, but there has been limited success
so far on combining chemotherapy with an ICI or with sequential
therapy. In order to tackle the problem of ICI resistance, we need a
biology-first approach, followed by precision immunotherapy. This
is a key challenge for early-phase trials.
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